A citation-based method for searching scientific literature

B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh, D B Rawlins, N C Goodwin, R Mabon, B A Harrison, A Wilson, A Sands, D R Powell. Clin. Pharmacol. Ther. 2012
Times Cited: 137



R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
Times Cited: 282




List of shared articles



Times cited

SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy.
Jaspreet Kalra, Suresh Babu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram, Arti Dhar. Fundam Clin Pharmacol 2020
1

SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
Heeyoung Chae, Robert Augustin, Eva Gatineau, Eric Mayoux, Mohammed Bensellam, Nancy Antoine, Firas Khattab, Bao-Khanh Lai, Davide Brusa, Birgit Stierstorfer,[...]. Mol Metab 2020
0

Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari. Cardiovasc Diabetol 2019
18

What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
5

Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study.
Tomoho Noda, Emi Ebihara, Hiroaki Ueno, Keisuke Sadohara, Yuri Tanaka, Yuuma Nagatomo, Yousuke Murakami, Shinichi Yonamine, Wakaba Tsuchimochi, Hideyuki Sakoda,[...]. Diabetes Ther 2019
1

Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes.
Reyhaneh Moradi-Marjaneh, Maryam Paseban, Amirhossein Sahebkar. Phytother Res 2019
2



Development of SGLT1 and SGLT2 inhibitors.
Timo Rieg, Volker Vallon. Diabetologia 2018
42


Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.
Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong-Min Liu. Expert Opin Drug Metab Toxicol 2017
8

C-Glycopyranosyl Arenes and Hetarenes: Synthetic Methods and Bioactivity Focused on Antidiabetic Potential.
Éva Bokor, Sándor Kun, David Goyard, Marietta Tóth, Jean-Pierre Praly, Sébastien Vidal, László Somsák. Chem. Rev. 2017
28

Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
Yao Li, Zongjun Shi, Lei Chen, Suxin Zheng, Sheng Li, Bo Xu, Zhenhong Liu, Jianyu Liu, Chongyang Deng, Fei Ye. J. Med. Chem. 2017
5

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date.
Francesca Cinti, Simona Moffa, Flavia Impronta, Chiara Ma Cefalo, Vinsin A Sun, Gian Pio Sorice, Teresa Mezza, Andrea Giaccari. Drug Des Devel Ther 2017
13



The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.
K Pafili, E Maltezos, N Papanas. Expert Opin Investig Drugs 2016
6


Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.
Sunder Mudaliar, David Polidori, Brian Zambrowicz, Robert R Henry. Diabetes Care 2015
97